AOD-9604 vs HGH Fragment 176-191

If you have spent any time researching peptides for fat loss, you have probably come across two names that sound almost interchangeable: AOD-9604 and HGH Fragment 176-191. They are related. They are often discussed in the same breath. But they are not identical, and the differences matter.

This article breaks down both compounds, explains where they come from, what the research shows and how they compare in practice.

Where Do These Compounds Come From?

To understand both peptides, you need to start with human growth hormone (HGH).

HGH is a 191-amino acid peptide hormone produced by the pituitary gland. Among its many roles, HGH stimulates lipolysis (the breakdown and release of fat from fat cells). For decades, researchers knew that HGH had fat-burning properties, but using exogenous HGH to achieve them came with significant drawbacks: insulin resistance, joint swelling, increased cancer risk and the suppression of natural HGH production.

The logical question became: which part of the HGH molecule is responsible for the fat-burning effects? And could you isolate that fragment to get the metabolic benefits without the risks?

The answer, after significant research, was yes. The fat-burning activity of HGH appears to reside in a specific portion of the molecule: amino acids 176 through 191. This is the C-terminal fragment.

Both AOD-9604 and HGH Fragment 176-191 are derived from this portion of the HGH molecule, which is why they are so often discussed together.

HGH Fragment 176-191: The Original Extract

HGH Fragment 176-191 is a straight peptide representation of amino acids 176 to 191 of the HGH molecule. It was one of the earlier compounds studied in the context of isolated fat-burning peptides.

Mechanism of action:
Like HGH itself, Fragment 176-191 stimulates lipolysis: the process by which triglycerides stored in fat cells are broken down into free fatty acids and released into circulation to be used as fuel.

Importantly, it appears to do this without mimicking HGH's effects on insulin resistance. Natural HGH at high levels reduces the body's sensitivity to insulin, which is one of the main concerns with exogenous HGH use. Fragment 176-191 does not appear to trigger this effect at research doses.

What the research shows:
Animal studies have consistently shown meaningful reductions in body fat with Fragment 176-191. Human clinical data is more limited, but early trials produced promising results.

One of the challenges with Fragment 176-191 is its relatively short half-life. It is broken down relatively quickly in the body, which affects how it is typically dosed.

AOD-9604: The Modified Version

AOD-9604 (Anti-Obesity Drug 9604) was developed by Australian researchers at Monash University who were specifically trying to optimise the fat-burning fragment of HGH for pharmaceutical use.

AOD-9604 is a modified version of HGH Fragment 176-191. The modification involves the addition of a tyrosine amino acid at the N-terminus (the start of the peptide chain). This structural change was made to improve the peptide's stability and bioavailability.

How it differs from Fragment 176-191:
The tyrosine modification gives AOD-9604 slightly different pharmacokinetic properties. Some research suggests it has a more favourable stability profile. The compound progressed further into clinical development than Fragment 176-191, reaching Phase 2 and Phase 3 clinical trials for obesity treatment.

What the clinical research shows:
AOD-9604's clinical development was ultimately discontinued as a pharmaceutical product after Phase 3 trials did not demonstrate sufficient efficacy at the doses tested for the primary endpoint. However, the compound was shown to be safe and well-tolerated, with no significant adverse effects related to blood sugar, insulin or growth-related pathways.

The interesting nuance is that the Phase 3 programme used very specific dosing parameters optimised for a pharmaceutical product with a particular regulatory profile. Researchers and practitioners in the peptide space often work with different dosing approaches, and anecdotal reports of fat loss effects are common.

Comparing the Two Compounds

In practical terms, the two compounds are more similar than they are different. Both target the same fundamental mechanism. The structural difference between them is relatively minor, and the choice between them often comes down to availability and supplier quality.

What These Compounds Are Not

It is worth being clear about the limitations of both compounds, because the marketing around fat-burning peptides can overstate what is achievable.

Neither AOD-9604 nor HGH Fragment 176-191 is a substitute for a caloric deficit. Lipolysis, the process both compounds stimulate, releases fat into circulation. But released fat is only burned as energy if there is a metabolic demand for it. Without appropriate diet and exercise, mobilised fat can be re-stored.

Think of these compounds as tools that may support and enhance the fat loss process when the fundamental lifestyle conditions are in place, not as standalone solutions.

They are also not equivalent to GLP-1 compounds in terms of the magnitude of weight loss achievable. GLP-1 agonists like Semaglutide and Tirzepatide produce more substantial and consistent weight loss in clinical data. Fragment-based compounds are often used as one component of a broader fat loss protocol rather than as the primary intervention.

Dosing Considerations

Both compounds are typically administered subcutaneously once or twice daily. Common research protocols use doses in the range of 200 to 300mcg per injection. Given the short half-life of both compounds, dosing before exercise or first thing in the morning on an empty stomach is common in practice.

As always, protocol design should account for individual response, and it is worth starting conservatively and assessing tolerance before increasing dose or frequency.

Which One Should You Choose?

For most people, the choice between the two is secondary to sourcing quality. Both compounds work through the same mechanism, and the structural difference between them is subtle. What matters far more is whether the compound you purchase has been independently tested for purity and potency.

If you are considering either compound as part of a fat loss protocol, our team is happy to discuss how it might fit alongside other elements of your approach.

Disclaimer: The information in this article is for educational purposes only. STRIATA peptides are research compounds and are not approved medicines. Always consult a qualified healthcare professional before beginning any protocol.